Nedderman A - Search Results

1

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, Cole S, Gibson KR, Jones R, Morao I, Nedderman A, Omoto K, Robinson C, Ryckmans T, Skinner K, Stupple P, Waldron G. Skerratt SE, et al. Among authors: nedderman a. J Med Chem. 2016 Nov 23;59(22):10084-10099. doi: 10.1021/acs.jmedchem.6b00850. Epub 2016 Nov 4. J Med Chem. 2016. PMID: 27766865

2

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. Roffey SJ, et al. Among authors: nedderman an. Drug Metab Dispos. 2003 Jun;31(6):731-41. doi: 10.1124/dmd.31.6.731. Drug Metab Dispos. 2003. PMID: 12756205

3

Molecular basis for methoxyamine initiated mutagenesis. 1H nuclear magnetic resonance studies of base-modified oligodeoxynucleotides.

Stone MJ, Nedderman AN, Williams DH, Lin PK, Brown DM. Stone MJ, et al. Among authors: nedderman an. J Mol Biol. 1991 Dec 5;222(3):711-23. doi: 10.1016/0022-2836(91)90507-3. J Mol Biol. 1991. PMID: 1660932

4

Molecular basis for methoxyamine-initiated mutagenesis: 1H nuclear magnetic resonance studies of oligonucleotide duplexes containing base-modified cytosine residues.

Nedderman AN, Stone MJ, Williams DH, Lin PK, Brown DM. Nedderman AN, et al. J Mol Biol. 1993 Apr 5;230(3):1068-76. doi: 10.1006/jmbi.1993.1219. J Mol Biol. 1993. PMID: 8478918

5

A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P. Walker D, et al. Among authors: nedderman a. Chem Res Toxicol. 2009 Oct;22(10):1653-62. doi: 10.1021/tx900213j. Chem Res Toxicol. 2009. PMID: 19715349 Review.

6

Metabolites in safety testing: metabolite identification strategies in discovery and development.

Nedderman AN. Nedderman AN. Biopharm Drug Dispos. 2009 May;30(4):153-62. doi: 10.1002/bdd.660. Biopharm Drug Dispos. 2009. PMID: 19544286

7

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Walker DK, et al. Among authors: nedderman an. Drug Metab Dispos. 2005 Apr;33(4):587-95. doi: 10.1124/dmd.104.002626. Epub 2005 Jan 13. Drug Metab Dispos. 2005. PMID: 15650075 Clinical Trial.

8

A sensitive HPLC-MS-MS assay for quantitative determination of midazolam in dog plasma.

Harris SR, Gedge JI, Nedderman AN, Roffey SJ, Savage M. Harris SR, et al. Among authors: nedderman an. J Pharm Biomed Anal. 2004 Apr 1;35(1):127-34. doi: 10.1016/j.jpba.2003.12.023. J Pharm Biomed Anal. 2004. PMID: 15030887

9

Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity.

Allan GA, Gedge JI, Nedderman AN, Roffey SJ, Small HF, Webster R. Allan GA, et al. Among authors: nedderman an. Xenobiotica. 2006 May;36(5):399-418. doi: 10.1080/00498250600618177. Xenobiotica. 2006. PMID: 16854779

10

The use of 96-well Scintiplates to facilitate definitive metabolism studies for drug candidates.

Nedderman AN, Savage ME, White KL, Walker DK. Nedderman AN, et al. J Pharm Biomed Anal. 2004 Feb 18;34(3):607-17. doi: 10.1016/s0731-7085(03)00575-2. J Pharm Biomed Anal. 2004. PMID: 15127817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters